[{"source": "wsj", "link": "https://www.wsj.com/articles/apple-exxon-mobil-rivian-stocks-that-defined-the-week-11646436656", "title": "Apple, Exxon Mobil, Rivian: Stocks That Defined the Week", "date": "2022-03-04 18:30", "summary": "Here are seven major companies whose stocks moved on the week's news. Apple Inc.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple, Exxon Mobil, Rivian: Stocks That Defined the Week. Here are seven major companies whose stocks moved on the week's news. Apple Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they announced a new product.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they announced a new product.\n- Rivian Automotive, LLC (private) will increase because they announced a new product."}, {"source": "wsj", "link": "https://www.wsj.com/articles/global-stocks-markets-dow-update-03-04-2022-11646371339", "title": "Dow Declines to End Week as Russia, Ukraine Concerns Mount", "date": "2022-03-04 18:13", "summary": "Strong U.S. jobs number wasn't enough to lift stocks. The Dow Jones Industrial Average ended its fourth week of losses and bond yields recorded their biggest one-week decline since March 2020 as Russia's military campaign in Ukraine intensified.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Dow Declines to End Week as Russia, Ukraine Concerns Mount. Strong U.S. jobs number wasn't enough to lift stocks. The Dow Jones Industrial Average ended its fourth week of losses and bond yields recorded their biggest one-week decline since March 2020 as Russia's military campaign in Ukraine intensified.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJI) will continue to decline because of the mounting tensions between Russia and Ukraine.\n- The S&P 500 (NYSE: SPX) will continue to decline because of the mounting tensions between Russia and Ukraine.\n- The Nasdaq Composite (NASDAQ: COMP) will continue to decline because of the mounting tensions between Russia and Ukraine."}, {"source": "wsj", "link": "https://www.wsj.com/articles/activision-ceo-bobby-kotick-steps-down-from-coca-cola-board-11646428990", "title": "Activision CEO Bobby Kotick to Step Down From Coca-Cola Board", "date": "2022-03-04 17:41", "summary": "The boss of the videogame publisher has served as a director for the company since 2012. Coca-Cola Co. said Activision Blizzard Inc. Chief Executive Bobby Kotick won't stand for re-election to its board of directors.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Activision CEO Bobby Kotick to Step Down From Coca-Cola Board. The boss of the videogame publisher has served as a director for the company since 2012. Coca-Cola Co. said Activision Blizzard Inc. Chief Executive Bobby Kotick won't stand for re-election to its board of directors.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co. (NYSE: KO) will increase because Bobby Kotick is stepping down and they need a new director.\n- Activision Blizzard Inc. (NASDAQ: ATVI) will decrease because Bobby Kotick is stepping down and they need a new CEO."}, {"source": "wsj", "link": "https://www.wsj.com/articles/commodity-funds-draw-bets-ukraine-invasion-russia-sanctions-will-stoke-rally-11646370755", "title": "Commodity Funds Draw Bets Ukraine War Will Stoke Rally", "date": "2022-03-04 16:45", "summary": "War grips global markets, lifting prices of raw materials including wheat and aluminum as investors wager on persistence of inflation. Investors are raising bets that the invasion of Ukraine and sanctions on Russia will further fuel an already-hot commodities rally.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Commodity Funds Draw Bets Ukraine War Will Stoke Rally. War grips global markets, lifting prices of raw materials including wheat and aluminum as investors wager on persistence of inflation. Investors are raising bets that the invasion of Ukraine and sanctions on Russia will further fuel an already-hot commodities rally.\"\n\nStock Prediction(s):", "Prediction": "\n- Agricultural commodities funds (e.g. the ETFs DBA, JJA, and CORN) will increase because of the potential for increased global demand for commodities due to the war.\n- Gold funds (e.g. the ETFs GLD, IAU, and SGOL) will increase because of the potential for increased global demand for commodities due to the war.\n- Steel funds (e.g. the ETFs SLX and STLD) will increase because of the potential for increased global demand for commodities due to the war."}, {"source": "wsj", "link": "https://www.wsj.com/articles/how-mortgage-interest-rate-deduction-works-2022-11646429952", "title": "Mortgage Interest Deduction: How It Works In 2022", "date": "2022-03-04 16:39", "summary": "The expansion of the standard deduction and a lower limit on deductible mortgage debt mean fewer filers are taking this popular write-off. The number of taxpayers claiming mortgage interest deductions on Schedule A has dropped sharply since the 2017 tax overhaul enacted both direct and indirect curbs on them. For 2019, about 13 million filers claimed the deduction vs. about 33 million for 2017, according to the latest IRS data.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mortgage Interest Deduction: How It Works In 2022. The expansion of the standard deduction and a lower limit on deductible mortgage debt mean fewer filers are taking this popular write-off. The number of taxpayers claiming mortgage interest deductions on Schedule A has dropped sharply since the 2017 tax overhaul enacted both direct and indirect curbs on them. For 2019, about 13 million filers claimed the deduction vs. about 33 million for 2017, according to the latest IRS data.\"\n\nStock Prediction(s):", "Prediction": "\n- The housing market will decrease because of the decrease in the number of people taking the mortgage interest deduction.\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will decrease because of the decrease in the number of people taking the mortgage interest deduction.\n- Real estate investment trusts such as Simon Property Group, Inc. (NYSE: SPG) and Equity Residential (NYSE: EQR) will decrease because of the decrease in the number of people taking the mortgage interest deduction."}, {"source": "wsj", "link": "https://www.wsj.com/articles/u-s-funding-markets-show-signs-of-stability-despite-russia-sanctions-11646359036", "title": "U.S. Funding Markets Show Signs of Stability Despite Russia Sanctions", "date": "2022-03-04 16:00", "summary": "Borrowing rates have ticked up, but there are few indications of cash-hoarding after steps are taken to isolate the Ukraine invader from global financial system. U.S. funding markets have remained relatively calm in recent days, easing the most-immediate concerns that sanctions against Russia would disrupt the basic functioning of the global financial system.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Funding Markets Show Signs of Stability Despite Russia Sanctions. Borrowing rates have ticked up, but there are few indications of cash-hoarding after steps are taken to isolate the Ukraine invader from global financial system. U.S. funding markets have remained relatively calm in recent days, easing the most-immediate concerns that sanctions against Russia would disrupt the basic functioning of the global financial system.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the few banks that have been unaffected by the sanctions.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the few banks that have been unaffected by the sanctions.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because they are one of the few banks that have been unaffected by the sanctions.\n- Morgan Stanley (NYSE: MS) will increase because they are one of the few banks that have been unaffected by the sanctions.\n- Citigroup Inc. (NYSE: C)"}, {"source": "wsj", "link": "https://www.wsj.com/articles/disney-to-roll-out-cheaper-ad-supported-subscription-in-late-2022-11646405231", "title": "Disney+ to Roll Out Cheaper, Ad-Supported Subscription", "date": "2022-03-04 13:12", "summary": "Disney joins competitors WarnerMedia, NBCUniversal and Paramount in ad-supported model as pressure builds to jump-start subscriber growth. Walt Disney Co. told investors just over a year ago that the idea of a cheaper, ad-supported subscription offering for its Disney+ streaming platform was anathema.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Disney+ to Roll Out Cheaper, Ad-Supported Subscription. Disney joins competitors WarnerMedia, NBCUniversal and Paramount in ad-supported model as pressure builds to jump-start subscriber growth. Walt Disney Co. told investors just over a year ago that the idea of a cheaper, ad-supported subscription offering for its Disney+ streaming platform was anathema.\"\n\nStock Prediction(s):", "Prediction": "\n- Disney (NYSE: DIS) will decrease because they are joining the competition by offering a cheaper, ad-supported subscription.\n- WarnerMedia (NYSE: TWX) will increase because they were one of the first to offer a cheaper, ad-supported subscription.\n- NBCUniversal (NYSE: CMCSA) will increase because they were one of the first to offer a cheaper, ad-supported subscription.\n- Paramount (NYSE: VIAB) will increase because they were one of the first to offer a cheaper, ad-supported subscription."}, {"source": "wsj", "link": "https://www.wsj.com/articles/my-millennial-friends-rethink-life-i-should-too-11646342194", "title": "All My Millennial Friends Are Rethinking Their Lives. Maybe I Should, Too", "date": "2022-03-04 12:49", "summary": "In the Young Money column: I don't really know how big the gap is between what I want from life and how I'm living it. But it's time to figure it out.. Last spring, on a terrace overlooking Bryant Park in Manhattan, one of my closest friends-the first of several roommates in my 13 years of living in New York City-married his beautiful bride.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"All My Millennial Friends Are Rethinking Their Lives. Maybe I Should, Too. In the Young Money column: I don't really know how big the gap is between what I want from life and how I'm living it. But it's time to figure it out.. Last spring, on a terrace overlooking Bryant Park in Manhattan, one of my closest friends-the first of several roommates in my 13 years of living in New York City-married his beautiful bride.\"\n\nStock Prediction(s):", "Prediction": "\n- Eventual Home Inc (NYSE: EVENT) will increase because more and more millennials are rethinking their lives and deciding to buy homes.\n- The Home Depot, Inc. (NYSE: HD) will increase because more and more millennials are rethinking their lives and deciding to buy homes.\n- Lowe's Companies, Inc. (NYSE: LOW) will increase because more and more millennials are rethinking their lives and deciding to buy homes."}, {"source": "wsj", "link": "https://www.wsj.com/articles/reddit-apes-arent-blown-away-by-ken-griffins-hobby-11646416123", "title": "Reddit Apes Aren't Blown Away by Ken Griffin's Hobby", "date": "2022-03-04 12:48", "summary": "Citadel boss's 'Call of Duty' revelation draws snark online. Judging by the chatter on Reddit, Ken Griffin is some sort of cross between Darth Vader and Mr. Burns from \"The Simpsons\"-an all-powerful yet clueless financial villain.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Reddit Apes Aren't Blown Away by Ken Griffin's Hobby. Citadel boss's 'Call of Duty' revelation draws snark online. Judging by the chatter on Reddit, Ken Griffin is some sort of cross between Darth Vader and Mr. Burns from \"The Simpsons\"-an all-powerful yet clueless financial villain.\"\n\nStock Prediction(s):", "Prediction": "\n- Citadel LLC (NYSE: CLC) will decrease because their CEO is spending too much time playing video games and not enough time running the company.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will increase because their video games are more popular than ever, and more people are spending more time playing them."}, {"source": "wsj", "link": "https://www.wsj.com/articles/job-market-looks-even-tighter-as-covid-19-recedes-11646414426", "title": "Job Market Looks Even Tighter as Covid-19 Recedes", "date": "2022-03-04 12:20", "summary": "A robust employment report and receding infections point to an even hotter U.S. labor market this spring. The combination of falling Covid-19 cases and rising opportunities is drawing more people back into the job market. That doesn't mean it is getting easier for companies to hire.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Job Market Looks Even Tighter as Covid-19 Recedes. A robust employment report and receding infections point to an even hotter U.S. labor market this spring. The combination of falling Covid-19 cases and rising opportunities is drawing more people back into the job market. That doesn't mean it is getting easier for companies to hire.\"\n\nStock Prediction(s):", "Prediction": "\n- Unemployment will continue to decline because the job market is getting tighter and companies are struggling to find qualified employees.\n- Wage growth will continue to increase because the job market is getting tighter and companies are struggling to find qualified employees.\n- The S&P 500 will continue to increase because the job market is getting tighter and companies are struggling to find qualified employees."}, {"source": "wsj", "link": "https://www.wsj.com/articles/tesla-gets-approval-for-vehicle-production-in-germany-11646407608", "title": "Tesla Gets Approval to Start EV Production in Germany", "date": "2022-03-04 11:36", "summary": "Formal opening marks next step in Elon Musk's global expansion drive. BERLIN-Tesla Inc. has secured local approvals in Germany to formally begin electric-vehicle productions at its new plant outside Berlin, a key pillar of Chief Executive Elon Musk's push to rapidly boost output and sales.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Gets Approval to Start EV Production in Germany. Formal opening marks next step in Elon Musk's global expansion drive. BERLIN-Tesla Inc. has secured local approvals in Germany to formally begin electric-vehicle productions at its new plant outside Berlin, a key pillar of Chief Executive Elon Musk's push to rapidly boost output and sales.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will increase because they are expanding their production to Germany.\n- Volkswagen AG (OTCPK: VOW3) will decrease because they are a direct competitor of Tesla.\n- BMW AG (OTCPK: BMWYY) will decrease because they are a direct competitor of Tesla."}, {"source": "wsj", "link": "https://www.wsj.com/articles/stock-markets-usually-go-up-sometimes-they-go-away-russia-etf-11646411622", "title": "Stock Markets Usually Go Up. Sometimes, They Go Away.", "date": "2022-03-04 11:34", "summary": "Trading on the Moscow stock exchange was suspended this past week. It's the latest reminder to investors that markets aren't always liquid.. This week, the stock market shut down in Moscow, and Russian shares collapsed on other exchanges, including in London and New York. Exchange-traded funds specializing in Russian stocks are down 90% or more from their highs shortly before the invasion of Ukraine-but, as of Friday, most of them are also frozen.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stock Markets Usually Go Up. Sometimes, They Go Away.. Trading on the Moscow stock exchange was suspended this past week. It's the latest reminder to investors that markets aren't always liquid.. This week, the stock market shut down in Moscow, and Russian shares collapsed on other exchanges, including in London and New York. Exchange-traded funds specializing in Russian stocks are down 90% or more from their highs shortly before the invasion of Ukraine-but, as of Friday, most of them are also frozen.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will rebound because it is only temporary.\n- The market will rebound because it is only temporary.\n- The market will rebound because it is only temporary."}, {"source": "wsj", "link": "https://www.wsj.com/articles/crypto-frauds-target-ukrainian-donations-11646408697", "title": "Crypto Frauds Target Ukrainian Donations", "date": "2022-03-04 10:44", "summary": "Some schemes launched in wake of Russian invasion try to trick donors into sending crypto to fraudsters, research firm says. Cryptocurrency frauds are trying to take advantage of an outpouring of support for Ukraine.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Crypto Frauds Target Ukrainian Donations. Some schemes launched in wake of Russian invasion try to trick donors into sending crypto to fraudsters, research firm says. Cryptocurrency frauds are trying to take advantage of an outpouring of support for Ukraine.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will decrease because of the crypto frauds in Ukraine.\n- Ethereum (ETH) will decrease because of the crypto frauds in Ukraine.\n- Litecoin (LTC) will decrease because of the crypto frauds in Ukraine.\n- Ripple (XRP) will decrease because of the crypto frauds in Ukraine."}, {"source": "wsj", "link": "https://www.wsj.com/articles/hellman-friedman-takes-7-5-stake-in-software-maker-splunk-11646389802", "title": "Hellman & Friedman Takes 7.5% Stake in Software Maker Splunk", "date": "2022-03-04 10:18", "summary": "The private-equity firm's stake is worth about $1.4 billion. Private-equity firm Hellman & Friedman LLC has taken a 7.5% stake in Splunk Inc. worth about $1.4 billion, a big bet on the software company and its incoming chief executive.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hellman & Friedman Takes 7.5% Stake in Software Maker Splunk. The private-equity firm's stake is worth about $1.4 billion. Private-equity firm Hellman & Friedman LLC has taken a 7.5% stake in Splunk Inc. worth about $1.4 billion, a big bet on the software company and its incoming chief executive.\"\n\nStock Prediction(s):", "Prediction": "\n- Splunk Inc (NASDAQ: SPLK) will increase because they have a new investor with a lot of money.\n- Salesforce.com, inc. (NYSE: CRM) will increase because they are a direct competitor of Splunk, and this will put more pressure on them to succeed.\n- Workday, Inc. (NYSE: WDAY) will increase because they are a direct competitor of Splunk, and this will put more pressure on them to succeed."}, {"source": "wsj", "link": "https://www.wsj.com/articles/grabs-28-billion-market-plunge-shows-perils-of-spac-mergers-11646397492", "title": "Grab's Stock Plunge Shows the Perils of SPAC Mergers", "date": "2022-03-04 10:00", "summary": "Company is latest in a string of SPAC deals that have performed poorly in the stock market. Grab Holdings Ltd. , the Southeast Asian superapp that set a high watermark for SPAC mergers last year, has quickly become one of the market's biggest post-listing flops.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grab's Stock Plunge Shows the Perils of SPAC Mergers. Company is latest in a string of SPAC deals that have performed poorly in the stock market. Grab Holdings Ltd. , the Southeast Asian superapp that set a high watermark for SPAC mergers last year, has quickly become one of the market's biggest post-listing flops.\"\n\nStock Prediction(s):", "Prediction": "\n- Grab Holdings Ltd. (GRVY) will continue to decrease because their SPAC merger has not performed well in the stock market.\n- SPACs in general will decrease because of the Grab Holdings Ltd. example."}, {"source": "wsj", "link": "https://www.wsj.com/articles/how-us-stimulus-payments-helped-meme-stock-craze-11646341966", "title": "U.S. Stimulus Payments May Have Helped Fuel the Meme-Stock Craze", "date": "2022-03-04 10:00", "summary": "A new study finds that shares of meme stocks soared in the weeks after individual investors received their first two rounds of checks. Meme stocks were one of the biggest market phenomena during the pandemic. And federal stimulus payments appear to have done a lot to fuel the surge.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Stimulus Payments May Have Helped Fuel the Meme-Stock Craze. A new study finds that shares of meme stocks soared in the weeks after individual investors received their first two rounds of checks. Meme stocks were one of the biggest market phenomena during the pandemic. And federal stimulus payments appear to have done a lot to fuel the surge.\"\n\nStock Prediction(s):", "Prediction": "\n- The meme-stock craze is over, and all of the associated stocks will decrease.\n- The only meme-stocks that will survive are the ones that have a legitimate business model and are not just a fad."}, {"source": "wsj", "link": "https://www.wsj.com/articles/coal-runs-hot-as-russia-ukraine-war-risks-europes-climate-agenda-11646402902", "title": "Coal Runs Hot as Russia-Ukraine War Risks Europe's Climate Agenda", "date": "2022-03-04 09:08", "summary": "Utilities, traders jostle for coal amid concerns of deepening energy crisis, propelling prices to all-time highs. The war in Ukraine scrambled global energy markets, with one especially unloved commodity-coal-enjoying a renaissance as European countries look again at the dirty fuel to establish energy independence from Russia.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coal Runs Hot as Russia-Ukraine War Risks Europe's Climate Agenda. Utilities, traders jostle for coal amid concerns of deepening energy crisis, propelling prices to all-time highs. The war in Ukraine scrambled global energy markets, with one especially unloved commodity-coal-enjoying a renaissance as European countries look again at the dirty fuel to establish energy independence from Russia.\"\n\nStock Prediction(s):", "Prediction": "\n- Coal stocks will increase because of the war in Ukraine and the increased demand for coal.\n- Natural gas stocks will decrease because of the war in Ukraine and the increased demand for coal.\n- Solar stocks will decrease because of the war in Ukraine and the increased demand for coal."}, {"source": "wsj", "link": "https://www.wsj.com/articles/costco-smith-wesson-splunk-gap-broadcom-what-to-watch-when-the-stock-market-opens-today-11646394389", "title": "Costco, Smith & Wesson, Splunk, Gap, Broadcom: What to Watch When the Stock Market Opens Today", "date": "2022-03-04 08:13", "summary": "Smith & Wesson's earnings report missed the target; Clothing retailer Gap's results came in ahead of expectations. Stock futures and global stock indexes fell as concerns mounted about Russia's intensifying military campaign in Ukraine (live coverage). Russia's central bank kept the Moscow stock market largely closed for a fifth straight day. Here's what we're watching in Friday's trading:", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Costco, Smith & Wesson, Splunk, Gap, Broadcom: What to Watch When the Stock Market Opens Today. Smith & Wesson's earnings report missed the target; Clothing retailer Gap's results came in ahead of expectations. Stock futures and global stock indexes fell as concerns mounted about Russia's intensifying military campaign in Ukraine (live coverage). Russia's central bank kept the Moscow stock market largely closed for a fifth straight day. Here's what we're watching in Friday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because their earnings report was good.\n- Smith & Wesson Holding Corporation (NASDAQ: SWHC) will decrease because their earnings report was not good.\n- Gap Inc. (NYSE: GPS) will increase because their earnings report was good.\n- Broadcom Corporation (NASDAQ: BRCM) will decrease because their earnings report was not good."}, {"source": "wsj", "link": "https://www.wsj.com/articles/sony-honda-to-team-up-in-developing-selling-electric-vehicles-11646376814", "title": "Sony, Honda to Team Up in Developing, Selling Electric Vehicles", "date": "2022-03-04 08:10", "summary": "Companies plan joint venture that would start selling EVs in 2025. TOKYO- Honda Motor Co. and Sony Group Corp. said they were teaming up to build electric vehicles, bringing together two big Japanese brands that have missed out on some major technology trends this century.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sony, Honda to Team Up in Developing, Selling Electric Vehicles. Companies plan joint venture that would start selling EVs in 2025. TOKYO- Honda Motor Co. and Sony Group Corp. said they were teaming up to build electric vehicles, bringing together two big Japanese brands that have missed out on some major technology trends this century.\"\n\nStock Prediction(s):", "Prediction": "\n- Honda Motor Co. (NYSE: HMC) will increase because they are teaming up with Sony to develop and sell electric vehicles.\n- Sony Group Corp. (NYSE: SNE) will increase because they are teaming up with Honda to develop and sell electric vehicles."}, {"source": "wsj", "link": "https://www.wsj.com/articles/justice-department-investigates-chicken-companies-information-sharing-on-labor-11646397000", "title": "U.S. Antitrust Probe Eyes Poultry Firms' Labor Practices", "date": "2022-03-04 07:30", "summary": "Justice Department starts civil antitrust probe to examine if an information exchange contributed to keeping wages lower for workers. The Justice Department is investigating whether poultry companies have engaged in anticompetitive sharing about employment practices that held down plant workers' wages, according to people familiar with the matter.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Antitrust Probe Eyes Poultry Firms' Labor Practices. Justice Department starts civil antitrust probe to examine if an information exchange contributed to keeping wages lower for workers. The Justice Department is investigating whether poultry companies have engaged in anticompetitive sharing about employment practices that held down plant workers' wages, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Tyson Foods, Inc. (NYSE: TSN) will decrease because they are one of the companies being investigated for antitrust practices.\n- Pilgrim's Pride Corporation (NASDAQ: PPC) will decrease because they are one of the companies being investigated for antitrust practices.\n- Sanderson Farms, Inc. (NASDAQ: SAFM) will decrease because they are one of the companies being investigated for antitrust practices."}, {"source": "wsj", "link": "https://www.wsj.com/articles/batman-has-a-big-hole-to-fill-for-theaters-11646395201", "title": "Batman Has a Big Hole to Fill for Theaters", "date": "2022-03-04 07:00", "summary": "The box office is now fully dependent on superhero blockbusters, leaving Wall Street skeptical of a full recovery for cinemas. Such is the state of America's movie theater industry that even the bleakest of superheroes is being counted on to brighten up the business.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Batman Has a Big Hole to Fill for Theaters. The box office is now fully dependent on superhero blockbusters, leaving Wall Street skeptical of a full recovery for cinemas. Such is the state of America's movie theater industry that even the bleakest of superheroes is being counted on to brighten up the business.\"\n\nStock Prediction(s):", "Prediction": "\n- Cinemark Holdings, Inc. (NYSE: CNK) will increase because they are one of the few theater chains that has a strong lineup of superhero movies in the coming months.\n- AMC Entertainment Holdings, Inc. (NYSE: AMC) will increase because they are one of the few theater chains that has a strong lineup of superhero movies in the coming months.\n- Regal Entertainment Group (NYSE: RGC) will decrease because they are one of the few theater chains that does not have a strong lineup of superhero movies in the coming months."}, {"source": "wsj", "link": "https://www.wsj.com/articles/japan-sticks-to-russian-oil-and-gas-bucking-western-pullouts-11646392575", "title": "Japan Sticks to Russian Oil and Gas, Bucking Western Pullouts", "date": "2022-03-04 06:16", "summary": "Tokyo cites decades of investments in Sakhalin projects and need to avoid dependence on Middle East. TOKYO-The Japanese government and local companies are sticking with their Russian energy deals, defying a pullout led by Western companies.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Japan Sticks to Russian Oil and Gas, Bucking Western Pullouts. Tokyo cites decades of investments in Sakhalin projects and need to avoid dependence on Middle East. TOKYO-The Japanese government and local companies are sticking with their Russian energy deals, defying a pullout led by Western companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Mitsubishi Corp (OTCMKTS: MSBHY) will increase because they are one of the few companies still doing business with Russia, and they have a strong presence in the energy market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because they are one of the companies that have pulled out of Russia, and they are a major player in the energy market.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are one of the companies that have pulled out of Russia, and they are a major player in the energy market.\n- BP plc"}, {"source": "wsj", "link": "https://www.wsj.com/articles/why-does-the-u-s-still-buy-russian-oil-11646151935", "title": "Why Does the U.S. Buy Russian Oil?", "date": "2022-03-04 05:54", "summary": "Despite being the top global producer, the U.S. turns to Russian crude to service more-isolated coastal markets and keep refineries running at optimal levels. The fracking boom made America the world's biggest oil producer a few years ago, but the U.S. still imports millions of barrels each day from other parts of the world, including Russia.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Does the U.S. Buy Russian Oil?. Despite being the top global producer, the U.S. turns to Russian crude to service more-isolated coastal markets and keep refineries running at optimal levels. The fracking boom made America the world's biggest oil producer a few years ago, but the U.S. still imports millions of barrels each day from other parts of the world, including Russia.\"\n\nStock Prediction(s):", "Prediction": "\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are one of the few companies that can produce oil domestically and import it from other countries.\n- Chevron Corporation (NYSE: CVX) will increase because they are one of the few companies that can produce oil domestically and import it from other countries.\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because they are one of the few companies that can produce oil domestically and import it from other countries.\n- BP plc (NYSE: BP) will decrease because they are not as well-equipped to produce oil domestically and import it from other countries"}, {"source": "wsj", "link": "https://www.wsj.com/articles/why-chinas-banks-wont-come-to-russias-rescue-11646389803", "title": "Why China's Banks Won't Come to Russia's Rescue", "date": "2022-03-04 05:30", "summary": "The risk of additional sanctions deters Chinese lenders, while a fledgling payment network relies on the Swift global system. On paper, China's banks and its homegrown payments system could offer Russia respite from crippling Western sanctions. China has helped other nations evade sanctions, and both China and Russia share an interest in weakening the dollar's hold on the international financial system.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why China's Banks Won't Come to Russia's Rescue. The risk of additional sanctions deters Chinese lenders, while a fledgling payment network relies on the Swift global system. On paper, China's banks and its homegrown payments system could offer Russia respite from crippling Western sanctions. China has helped other nations evade sanctions, and both China and Russia share an interest in weakening the dollar's hold on the international financial system.\"\n\nStock Prediction(s):", "Prediction": "\n- The Bank of China Ltd. (OTC: BACHY) will increase because they are not afraid of sanctions, and they want to help Russia.\n- The Industrial and Commercial Bank of China Ltd. (OTC: IDCBY) will increase because they are not afraid of sanctions, and they want to help Russia.\n- The Agricultural Bank of China Ltd. (OTC: ACGBY) will increase because they are not afraid of sanctions, and they want to help Russia.\n- The China Construction Bank Corporation (OTC: CICHY) will increase because they are not afraid of sanctions,"}, {"source": "wsj", "link": "https://www.wsj.com/articles/is-it-the-end-of-the-road-for-computing-power-11646389802", "title": "Is It the End of the Road for Computing Power?", "date": "2022-03-04 05:30", "summary": "That phone in your pocket was predicted by Moore's Law, but it is bumping against its physical and economic limits. It may not be an actual law of nature, but a bold statement made decades ago has predicted the dizzying advance of technology. Now it is about to falter. The business that powers everything around us from cars to smartphones to our utilities faces a reckoning.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Is It the End of the Road for Computing Power?. That phone in your pocket was predicted by Moore's Law, but it is bumping against its physical and economic limits. It may not be an actual law of nature, but a bold statement made decades ago has predicted the dizzying advance of technology. Now it is about to falter. The business that powers everything around us from cars to smartphones to our utilities faces a reckoning.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will decrease because their main product is computing power, and this article predicts that this industry is about to falter.\n- Nvidia Corporation (NASDAQ: NVDA) will increase because they are not as reliant on computing power, and they are expanding into other industries.\n- Advanced Micro Devices, Inc. (NASDAQ: AMD) will increase because they are not as reliant on computing power, and they are expanding into other industries."}, {"source": "wsj", "link": "https://www.wsj.com/articles/chris-cocks-is-hasbros-gamer-in-chief-11646389842", "title": "Hasbro's Gamer in Chief", "date": "2022-03-04 05:30", "summary": "The toy maker's new CEO loves Dungeons & Dragons and Magic: The Gathering. Now he's playing against an activist investor, a surging rival and a slowing toy market.. PAWTUCKET, R.I.-Chris Cocks played with G.I. Joe and Transformers action figures as a child. Then he moved on to Dungeons & Dragons and Magic: The Gathering. He's still playing both at 48.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hasbro's Gamer in Chief. The toy maker's new CEO loves Dungeons & Dragons and Magic: The Gathering. Now he's playing against an activist investor, a surging rival and a slowing toy market.. PAWTUCKET, R.I.-Chris Cocks played with G.I. Joe and Transformers action figures as a child. Then he moved on to Dungeons & Dragons and Magic: The Gathering. He's still playing both at 48.\"\n\nStock Prediction(s):", "Prediction": "\n- Hasbro, Inc. (NASDAQ: HAS) will increase because their new CEO is a gamer and he is looking to expand the company's gaming division.\n- Mattel, Inc. (NASDAQ: MAT) will decrease because they are a direct competitor of Hasbro, and Hasbro is now looking to expand their gaming division."}, {"source": "wsj", "link": "https://www.wsj.com/articles/how-much-more-expensive-used-and-new-cars-are-in-2022-11646350633", "title": "How Much More Used and New Cars Cost Now", "date": "2022-03-04 05:30", "summary": "See for yourself how buying and owning a vehicle costs more than it has in years. We are delighted that you'd like to resume your subscription.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Much More Used and New Cars Cost Now. See for yourself how buying and owning a vehicle costs more than it has in years. We are delighted that you'd like to resume your subscription.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because the cost of vehicles is going up, and they are one of the leading car manufacturers.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because the cost of vehicles is going up, and they are one of the leading electric car manufacturers.\n- General Motors Company (NYSE: GM) will increase because the cost of vehicles is going up, and they are one of the leading car manufacturers.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because the cost of vehicles is going up, and they are one of"}, {"source": "wsj", "link": "https://www.wsj.com/articles/europes-food-delivery-stocks-are-appetizingly-cheap-11646387187", "title": "Europe's Food Delivery Stocks Are Appetizingly Cheap", "date": "2022-03-04 04:46", "summary": "Shares in takeout apps such as Delivery Hero now trade below pre-Covid levels, despite new eating habits. Europe's fast-growing food apps can add inflation to their list of problems. But changes in consumer eating patterns caused by the pandemic are sticking so far and valuations seem undercooked.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Food Delivery Stocks Are Appetizingly Cheap. Shares in takeout apps such as Delivery Hero now trade below pre-Covid levels, despite new eating habits. Europe's fast-growing food apps can add inflation to their list of problems. But changes in consumer eating patterns caused by the pandemic are sticking so far and valuations seem undercooked.\"\n\nStock Prediction(s):", "Prediction": "\n- Delivery Hero SE (OTCMKTS: DHERY) will increase because their stock is trading below pre-Covid levels, and they are still seeing changes in consumer eating patterns.\n- Just Eat plc (LON: JE) will increase because their stock is trading below pre-Covid levels, and they are still seeing changes in consumer eating patterns.\n- Takeaway.com NV (AMS: TKWY) will increase because their stock is trading below pre-Covid levels, and they are still seeing changes in consumer eating patterns."}, {"source": "wsj", "link": "https://www.wsj.com/articles/carlos-ghosn-criticizes-judge-in-trial-in-tokyo-of-former-nissan-aide-11646317343", "title": "Carlos Ghosn Blasts Tokyo Judge Who Called Him Greedy", "date": "2022-03-04 21:21", "summary": "Japan court delivers a de facto verdict in case of former Nissan CEO, who says ruling shows why he needed to escape to Lebanon. TOKYO-A Tokyo judge lashed out at fugitive car executive Carlos Ghosn, calling him a greedy and malicious criminal, and Mr. Ghosn said the statements proved why he couldn't have gotten a fair trial in Japan.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Carlos Ghosn Blasts Tokyo Judge Who Called Him Greedy. Japan court delivers a de facto verdict in case of former Nissan CEO, who says ruling shows why he needed to escape to Lebanon. TOKYO-A Tokyo judge lashed out at fugitive car executive Carlos Ghosn, calling him a greedy and malicious criminal, and Mr. Ghosn said the statements proved why he couldn't have gotten a fair trial in Japan.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will decrease because Carlos Ghosn was a major shareholder and was recently ousted as CEO.\n- Nissan Motor Co Ltd (TSE: 7201) will decrease because Carlos Ghosn was a major shareholder and was recently ousted as CEO.\n- Mitsubishi Motors Corp (TSE: 7211) will decrease because Carlos Ghosn was a major shareholder and was recently ousted as CEO.\n- Ford Motor Co (NYSE: F) will decrease because Carlos Ghosn was a major shareholder and was recently ousted as CEO."}, {"source": "wsj", "link": "https://www.wsj.com/articles/once-slated-to-be-americas-priciest-home-the-one-sells-at-auction-for-just-126-million-11646353950", "title": "Once Slated to be America's Priciest Home, The One Sells at Auction for Just $126 Million", "date": "2022-03-04 19:32", "summary": "Developer Nile Niami once planned to list his L.A. megamansion for $500 million, but later faced construction delays and cost overruns. Once slated to list with a $500 million asking price, a Bel-Air megamansion known as The One has sold for just $126 million at a no-reserve auction, according to a spokeswoman at Concierge Auctions. The buyer, who couldn't immediately be identified, will also have to pay an auction premium, bringing their total bill to roughly $141 million.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Once Slated to be America's Priciest Home, The One Sells at Auction for Just $126 Million. Developer Nile Niami once planned to list his L.A. megamansion for $500 million, but later faced construction delays and cost overruns. Once slated to list with a $500 million asking price, a Bel-Air megamansion known as The One has sold for just $126 million at a no-reserve auction, according to a spokeswoman at Concierge Auctions. The buyer, who couldn't immediately be identified, will also have to pay an auction premium, bringing their total bill to roughly $141 million.\"\n\nStock Prediction(s):", "Prediction": "\n- The One's development delays and cost overruns will negatively impact the stock prices of developers such as Nile Niami, who are in direct competition with him.\n- Luxury homebuilders such as Toll Brothers, Inc. (NYSE: TOL) and KB Home (NYSE: KBH) will benefit from the news, as more high-end buyers will enter the market."}, {"source": "wsj", "link": "https://www.wsj.com/articles/hundreds-of-new-york-times-tech-staffers-vote-to-unionize-11646352666", "title": "Hundreds of New York Times Tech Staffers Vote to Unionize", "date": "2022-03-04 19:11", "summary": "Group of some 600 employees will form largest U.S. union of tech workers with bargaining rights, NewsGuild says. Tech staffers at New York Times Co. have voted to unionize, creating the largest union of tech workers with bargaining rights in the country, the NewsGuild of New York said Thursday.", "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. Researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hundreds of New York Times Tech Staffers Vote to Unionize. Group of some 600 employees will form largest U.S. union of tech workers with bargaining rights, NewsGuild says. Tech staffers at New York Times Co. have voted to unionize, creating the largest union of tech workers with bargaining rights in the country, the NewsGuild of New York said Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- The New York Times Co. (NYSE: NYT) will increase because their tech staff is unionized.\n- Other tech companies will also increase because they will have to compete with the New York Times Co. for talent."}]